AAAAAA

   
Results: 1-18 |
Results: 18
Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis
Authors: Tortora, G Caputo, R Damiano, V Bianco, R Fontanini, G Cuccato, S De Placido, S Bianco, AR Ciardiello, F
Citation: G. Tortora et al., Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis, CLIN CANC R, 7(8), 2001, pp. 2537-2544
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
Authors: Ciardiello, F Caputo, R Bianco, R Damiano, V Fentanini, G Cuccato, S De Placido, S Bianco, AR Tortora, G
Citation: F. Ciardiello et al., Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, CLIN CANC R, 7(5), 2001, pp. 1459-1465
Survival, quality of life and breast cancer
Authors: Mosconi, P Colozza, M Laurentiis, MD De Placido, S Maltoni, M
Citation: P. Mosconi et al., Survival, quality of life and breast cancer, ANN ONCOL, 12, 2001, pp. S15-S19
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
Authors: Ciardiello, F Bianco, R Damiano, V Fontanini, G Caputo, R Pomatico, G De Placido, S Bianco, AR Mendelsohn, J Tortora, G
Citation: F. Ciardiello et al., Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells, CLIN CANC R, 6(9), 2000, pp. 3739-3747
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production
Authors: Tortora, G Bianco, R Damiano, V Fontanini, G De Placido, S Bianco, AR Ciardiello, F
Citation: G. Tortora et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production, CLIN CANC R, 6(6), 2000, pp. 2506-2512
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
Authors: Ciardiello, F Caputo, R Bianco, R Damiano, V Pomatico, G De Placido, S Bianco, AR Tortora, G
Citation: F. Ciardiello et al., Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor, CLIN CANC R, 6(5), 2000, pp. 2053-2063
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
Authors: Bianco, C Bianco, R Tortora, G Damiano, V Guerrieri, P Montemaggi, P Mendelsohn, J De Placido, S Bianco, AR Ciardiello, F
Citation: C. Bianco et al., Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide, CLIN CANC R, 6(11), 2000, pp. 4343-4350
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma
Authors: Perrone, F Daniele, B Gaeta, GB Pignata, S Gallo, C Izzo, F Cuomo, O Capuano, G Ruggiero, G Mazzanti, R Farinati, F Elba, S Daniele, B Pignata, S Cremona, F Izzo, F Parisi, V Fiore, F Vallone, P Perrone, F Cuomo, O Di Palma, M Manno, E Militerno, G Budillon, G Capuano, G Cimino, L Pomponi, D Adinolfi, LE Ragone, E Ruggiero, G Utili, R Arena, U Di Fiore, G Gentilini, P Mazzanti, R Farinati, F Rinaldi, M Elba, S Coviello, A Manghisi, OG Crispino, B Laviscio, R Piaib, G Caporaso, N De Sio, I Belli, G Iannelli, A Santangelo, ML Gaeta, GB Ascione, T Giusti, G D'Angelo, V Francica, G Marone, G Pasquale, G Piccinino, F Stanzione, M Bianco, AR De Placido, S Palmieri, G D'Agostino, L Mattera, D Puzziello, A Aiello, A Ferrau, O Freni, MA Aloisio, V Giorgio, A Perrotta, A Calandra, M Castellano, L Blanco, CD Castiglione, F Mazzacca, G Rispo, A Colurcio, R Galanti, B Russo, M Palmentieri, B Persico, M Felder, M Zancanella, L Belli, M Colantuoni, G De Sena, G Guardascione, F Petrelli, G Lamorgese, B Manzione, L Pedicini, T D'Aprile, M Gallo, C
Citation: F. Perrone et al., Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma, HEPATOLOGY, 31(4), 2000, pp. 840-845
Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer
Authors: De Placido, S Tramontana, S Ferrari, E De Matteis, A Lauria, R Perrone, F Bianco, AR Gallo, C Ricchi, P De Placido, G Pignata, S
Citation: S. De Placido et al., Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer, ANTICANC R, 20(5C), 2000, pp. 4023-4029
Vinorelbine plus mitomycin C as second-line treatment of metastatic breastcancer: A two-stage phase 2 study
Authors: De Placido, S Lauria, R Perrone, F Lombardi, AV Carlomagno, C Varriale, E Costanzo, R Leo, L De Laurentiis, M Bianco, AR
Citation: S. De Placido et al., Vinorelbine plus mitomycin C as second-line treatment of metastatic breastcancer: A two-stage phase 2 study, ONCOL-BASEL, 58(1), 2000, pp. 8-14
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A
Authors: Ciardiello, F Caputo, R Pomatico, G De Laurentiis, M De Placido, S Bianco, AR Tortora, G
Citation: F. Ciardiello et al., Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A, INT J CANC, 85(5), 2000, pp. 710-715
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas
Authors: Pepe, S Ruggiero, A D'Acquisto, M De Laurentiis, M De Placido, S Sandomenico, C Staibano, S De Rosa, G Lucariello, A D'Armiento, M Bianco, AR
Citation: S. Pepe et al., Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas, CANCER, 89(5), 2000, pp. 1065-1075
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
Authors: Ciardiello, F Bianco, R Damiano, V De Lorenzo, S Pepe, S De Placido, S Fan, Z Mendelsohn, J Bianco, AR Tortora, G
Citation: F. Ciardiello et al., Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225, CLIN CANC R, 5(4), 1999, pp. 909-916
A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients
Authors: De Laurentiis, M De Placido, S Bianco, AR Clark, GM Ravdin, PM
Citation: M. De Laurentiis et al., A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients, CLIN CANC R, 5(12), 1999, pp. 4133-4139
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up
Authors: De Placido, S Carlomagno, C Ciardiello, F De Laurentiis, M Pepe, S Ruggiero, A Tortora, G Panico, L D'Antonio, A Pettinato, G Petrella, G Bianco, AR
Citation: S. De Placido et al., Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up, CLIN CANC R, 5(10), 1999, pp. 2854-2859
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer
Authors: De Placido, S Lauria, R Carlomagno, C Perrone, F De Laurentiis, M Gallo, C Martignetti, A Bellelli, T Limite, G Petrella, G Bianco, AR
Citation: S. De Placido et al., The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer, INT J ONCOL, 15(2), 1999, pp. 339-346
A phase I study of paclitaxel and epirubicin, without and with filgrastim,for the treatment of platinum-resistant advanced ovarian cancer
Authors: Lauria, R Ferrari, E Tramontana, S Morabito, A Perrone, F Maffeo, A Fiorentino, R Casella, G Iodice, F Ricchi, P Carlomagno, C Varriale, E De Placido, G De Placido, S Bianco, AR Pignata, S
Citation: R. Lauria et al., A phase I study of paclitaxel and epirubicin, without and with filgrastim,for the treatment of platinum-resistant advanced ovarian cancer, ONCOL-BASEL, 56(4), 1999, pp. 267-273
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
Authors: De Placido, S Carlomagno, C De Laurentiis, M Bianco, AR
Citation: S. De Placido et al., c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients, BREAST CANC, 52(1-3), 1998, pp. 55-64
Risultati: 1-18 |